Cerebral venous thrombosis (CVT) is a rare clotting disorder that mainly affects younger females. In order to achieve recanalization of cerebral veins and reduce the risk of venous thromboembolism (VTE), current guidelines recommend anticoagulation therapy for a period of 3 to 12 months for patients with CVT [1,2]. This therapy usually involves the use of vitamin K antagonists (VKAs) or low-molecular-weight heparin (LMWH). However, recent studies have shown that direct oral anticoagulants (DOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban have several advantages over VKAs in specific population groups requiring thrombosis prophylaxis [3].
